JADELLE Drug Patent Profile
✉ Email this page to a colleague
When do Jadelle patents expire, and what generic alternatives are available?
Jadelle is a drug marketed by Population Council and is included in one NDA.
The generic ingredient in JADELLE is levonorgestrel. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the levonorgestrel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Jadelle
A generic version of JADELLE was approved as levonorgestrel by NOVEL LABS INC on February 22nd, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for JADELLE?
- What are the global sales for JADELLE?
- What is Average Wholesale Price for JADELLE?
Summary for JADELLE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 8 |
| Patent Applications: | 3,682 |
| DailyMed Link: | JADELLE at DailyMed |
Recent Clinical Trials for JADELLE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pittsburgh | Phase 2 |
| Chulalongkorn University | Phase 4 |
| Infectious Diseases Institute, Uganda | Phase 2 |
US Patents and Regulatory Information for JADELLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Population Council | JADELLE | levonorgestrel | IMPLANT;IMPLANTATION | 020544-001 | Nov 1, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
